Clinical trials: sponsored by RemeGen Co., Ltd.
Healthy
A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects
to evaluate the pharmacokinetics, and pharmacodynamics of a single dose of Tai Ai injection in healthy adult Chinese subjects
- Trial name
- NCT04235933
- Testing
- Tai Ai(RC18) 80mg, Tai Ai(RC18) 160mg, RC18 240mg
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- RemeGen Co., Ltd.
Urothelial Carcinoma, Advanced Cancer
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with local advanced or metastatic HER2 positive endothelial cancer.
- Trial name
- NCT03507166
- Testing
- RC48-ADC
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- RemeGen Co., Ltd.
Moderate and Severe Rheumatoid Arthritis
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
This is a phase Ⅱ, placebo-controlled, multicenter, dynamic randomized, double blind study of the efficacy and safety of RC18, a recombinant human B lymphocyte stimulating factor receptor-antibody fusion protein in subjects with…
- Trial name
- NCT02882087
- Testing
- RC18 160 mg plus MTX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- RemeGen Co., Ltd.